What if the idea that each of us has one genome is off by over a trillion-fold? Genetic changes make each cell's genome slightly different. At Quotient, we’re using the first ever #SomaticGenomics platform to explore this universe of somatic genome variation and reveal novel drug targets. Learn more: https://bit.ly/47pFujv
关于我们
Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com
- 网站
-
https://quotient-tx.com/
Quotient Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
Quotient Therapeutics员工
-
Zeynep Kalender Atak
Principal Scientist, Computational Biology Team Lead at Quotient Therapeutics
-
Janeta Popovici-Muller
Drug Discovery Leader
-
Simon Brunner
Flagship Pioneering | Co-founder at Quotient Therapeutics | Ex-BCG
-
Rui Wang
Immunologist, seasoned biology leader adept in strategic research, team management and project execution
动态
-
Congratulations to our academic co-founder, Sir Mike Stratton, on receiving the Royal Medal 2024 in recognition of his outstanding contributions to #cancer genomics. We are proud to use his foundational research as a guide while we pioneer the field of #SomaticGenomics. #RSMedals?
Congratulations to Sir Mike Stratton and Sam Behjati, who have been awarded by the The Royal Society for their pioneering work in cancer research ?? ? They are among 25 Medal and Award winners recognised this year by the Royal Society, the UK’s national academy of sciences. Mike received the Royal Medal (Biological) for his work in cancer genomics, including discovering cancer-causing genes and mutational signatures, and establishing the Cancer Genome Project. His research also identified the BRCA2 gene and sequenced the first complete cancer genome. Sam received the Francis Crick Medal and Lecture for his discoveries on the developmental origins of childhood cancers. As a practising consultant at Addenbrooke’s Hospital, he ensures that every child with a solid tumour in his region receives whole-genome sequencing, which allows for more precise diagnoses and targeted therapies. ? Read the full story https://lnkd.in/e3hmRxmj
-
Today we announced two research programs through Flagship Pioneering's strategic partnership with Pfizer to identify potential novel targets for the treatment of #cardiovascular and #renal diseases. Under the agreement, our #SomaticGenomics platform will analyze somatic mutations in diseased patient tissue to inform the discovery and development of potentially transformative therapies. Learn more: https://bit.ly/473ta8w
-
-
At Quotient, our boundless energy for science fuels creative problem-solving and groundbreaking ideas. Our Head of Data Infrastructure William Spooner says it best: Innovation is at the heart of our culture, guiding us to build the future of #SomaticGenomics. Learn more about what guides our team to success here: https://bit.ly/3WLvOei
-
-
?? Our #SomaticGenomics platform offers unparalleled capabilities to identify novel targets, revealing a path to create transformative therapeutics. Discover the future of genetics with our cutting-edge technology: https://bit.ly/3AkWg71
-
-
Are you attending #SXSW2025? Our proposed panel, “The Secret Life of DNA,” will explore advances in technology that allow us to uncover unknown regions of the genome & its potential impact on medicine. Vote for us using SXSW's #PanelPicker through 8/18: https://bit.ly/3AsjGYj
-
-
We're pleased to share that academic co-founder Peter Campbell, Ph.D., who pioneered somatic genomics research while at the Wellcome Sanger Institute, is now joining the Quotient team as chief scientific officer. We look forward to advancing the first ever #SomaticGenomics platform under his leadership. Read more in our press release: https://bit.ly/3YBCkqS
-
-
???? Today we celebrate the birthday of Rosalind Franklin, whose groundbreaking X-ray diffraction work was key to discovering #DNA's structure. Her legacy has paved the way for our work in #SomaticGenomics and inspires our innovations every day.
-
-
Companies pioneering original science are key to discovering new medicines. As we explore our #SomaticGenomics platform, we’re proud to be part of the #FlagshipFounded ecosystem of companies, and the many more to come, taking bold scientific leaps for a better future for all.
Flagship?Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship?Founder and CEO Noubar Afeyan about?how we're?taking #BiggerLeaps by leveraging the power of generative AI,?forging?novel partnerships?with pharma to speed drug development, expanding globally, and?promoting?and hiring?top talent to our leadership ranks.?Read the full press release:?https://bit.ly/4eQfx05
-
Our academic co-founders contributed to this 2023 study published in Cell Press, highlighting how somatic mutations in liver cells can help to identify adaptive pathways in metabolic liver disease. The research is encouraging as we explore the possibilities of our #SomaticGenomics Platform and human target selection. Read the study here: https://bit.ly/4eCnQfT
-